Trial · NCT00004732
Carotid Revascularization Endarterectomy Versus Stenting Trial
NCT00004732, Not applicable, Completed, Rutgers, The State University of New Jersey; results first posted 2013-12-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Carotid Revascularization Endarterectomy Versus Stenting Trial. Trials, record NCT00004732. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00004732
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Carotid Revascularization Endarterectomy Versus Stenting Trial
- NCT number
- NCT00004732
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,502 participants, actual
- Lead sponsor
- Rutgers, The State University of New Jersey
- Conditions
- Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
- Interventions
- Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
- First posted
- 2000-02-28
- Last updated
- 2017-05-17
- Results first posted
- 2013-12-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years. | 30 days and 4 years | The primary aim of CREST is to assess if the efficacy of CAS differs from that of CEA in preventing stroke, myocardial infarction and death during a 30-day peri-procedural period, or ipsilateral stroke over the follow-up period in patients with symptomatic (\>=50%) or asymptomatic (\>=60%) extracranial carotid stenosis. Four-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. |
| Secondary | Differential Efficacy of CAS and CEA in Male and Female Participants in the Primary Endpoint (Any Periprocedural Stroke, Myocardial Infarction, or Death or Postprocedural Ipsilateral Stroke). | 4 years | 4-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years. | 30 days and 4 years | Percentage | MEAN | |
| SECONDARY | Differential Efficacy of CAS and CEA in Male and Female Participants in the Primary Endpoint (Any Periprocedural Stroke, Myocardial Infarction, or Death or Postprocedural Ipsilateral Stroke). | 4 years | Percentage | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years. | Carotid-Artery Stenting | 7.2 | Standard Error 0.8 | Percentage | |
| Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years. | Carotid Endarterectomy | 6.8 | Standard Error 0.8 | Percentage | |
| Differential Efficacy of CAS and CEA in Male and Female Participants in the Primary Endpoint (Any Periprocedural Stroke, Myocardial Infarction, or Death or Postprocedural Ipsilateral Stroke). | Carotid-Artery Stenting | Men | 6.2 | Standard Error 0.9 | Percentage |
| Differential Efficacy of CAS and CEA in Male and Female Participants in the Primary Endpoint (Any Periprocedural Stroke, Myocardial Infarction, or Death or Postprocedural Ipsilateral Stroke). | Carotid Endarterectomy | Men | 6.8 | Standard Error 1.0 | Percentage |
| Differential Efficacy of CAS and CEA in Male and Female Participants in the Primary Endpoint (Any Periprocedural Stroke, Myocardial Infarction, or Death or Postprocedural Ipsilateral Stroke). | Carotid-Artery Stenting | Women | 8.9 | Standard Error 1.4 | Percentage |
| Differential Efficacy of CAS and CEA in Male and Female Participants in the Primary Endpoint (Any Periprocedural Stroke, Myocardial Infarction, or Death or Postprocedural Ipsilateral Stroke). | Carotid Endarterectomy | Women | 6.7 | Standard Error 1.3 | Percentage |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Carotid-Artery Stenting (CAS) | 1,262 | |
| Overall Study | STARTED | Carotid Endarterectomy (CEA) | 1,240 | |
| Overall Study | COMPLETED | Carotid-Artery Stenting (CAS) | 1,193 | |
| Overall Study | COMPLETED | Carotid Endarterectomy (CEA) | 1,129 | |
| Overall Study | NOT COMPLETED | Carotid-Artery Stenting (CAS) | 69 | |
| Overall Study | NOT COMPLETED | Carotid Endarterectomy (CEA) | 111 |
Source ClinicalTrials.gov
Adverse events38
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neurologic AE (non-endpoint, non-serious) | Nervous system disorders | Carotid-Artery Stenting | 65 | 1,262 | 81 |
| other | Neurologic AE (non-endpoint, non-serious) | Nervous system disorders | Carotid Endarterectomy | 72 | 1,240 | 83 |
| other | Hemorrhagic/vascular AE (not serious) | Vascular disorders | Carotid-Artery Stenting | 21 | 1,262 | 23 |
| other | Hemorrhagic/vascular AE (not serious) | Vascular disorders | Carotid Endarterectomy | 20 | 1,240 | 23 |
| other | Hemodynamic AE (not serious) | Blood and lymphatic system disorders | Carotid-Artery Stenting | 65 | 1,262 | 73 |
| other | Hemodynamic AE (not serious) | Blood and lymphatic system disorders | Carotid Endarterectomy | 45 | 1,240 | 50 |
| other | Infectious Disorder AE (not serious) | Infections and infestations | Carotid-Artery Stenting | 13 | 1,262 | 13 |
| other | Infectious Disorder AE (not serious) | Infections and infestations | Carotid Endarterectomy | 12 | 1,240 | 13 |
| other | Cardiovascular AE (non-endpoint, non-serious) | Cardiac disorders | Carotid-Artery Stenting | 34 | 1,262 | 41 |
| other | Cardiovascular AE (non-endpoint, non-serious) | Cardiac disorders | Carotid Endarterectomy | 36 | 1,240 | 42 |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Carotid-Artery Stenting | ||
| Total, all-cause mortality | Carotid Endarterectomy | ||
| Total, other adverse events | Carotid-Artery Stenting | 213 | 1,262 |
| Total, other adverse events | Carotid Endarterectomy | 212 | 1,240 |
| Total, serious adverse events | Carotid-Artery Stenting | 322 | 1,262 |
| Total, serious adverse events | Carotid Endarterectomy | 292 | 1,240 |
Source ClinicalTrials.gov
Papers43
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01NS038384 | Carotid Revascularization Endarterectomy vs Stenting Trial | BROTT, THOMAS G | UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 1999 to 2010 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Carotid-Artery Stenting vs Carotid Endarterectomy: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00004732
GET https://conductscience.org/api/trials/v1/NCT00004732/events?page=2